What we found on the web about Sirna
Small interfering RNA - Wikipedia, the free encyclopedia
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a ...
Sirna Therapeutics - Wikipedia, the free encyclopedia
Sirna Therapeutics was a San Francisco, California based biotechnology company that explores the use of RNA interference in human disease therapy. Sirna's development pipeline ...
What is siRNA and RNAi from Gene Link
What is siRNA and RNAi from Gene Link ... How does it work? Recent advances in molecular biology have shown that gene expression can be effectively silenced in a highly specific ...
RNA Interference (RNAi) Resource
Next Generation siRNA Technology to Make Your Silencing Roar Susan Magdaleno, PhD November ... RNAi in the News. Strong Immune Response To New SiRNA Drugs In Development May Cause ...
Guidelines for the selection of highly effective siRNA sequences for ...
Published online 9 February 2004. Nucleic Acids Research, 2004, Vol. 32, No. 3 936-948 © 2004 Oxford University Press Guidelines for the selection of highly effective siRNA ...
RNA Interference (RNAi) Resource
A gateway to all types of information about RNA interference (RNAi), including ... Calculating Gene Expression Changes and Variability in siRNA Experiments ...
RNA interference - Wikipedia, the free encyclopedia
Online article describing the basics of RNA Interference (RNAi) mechanism. ... Small interfering RNA strands (siRNA) are key to the RNAi process, and have ...
siRNA
leading worldwide source for research antibody and RNA interference products. World leader in: monoclonal and polyclonal research antibodies; siRNA, shRNA and Lentiviral products
Sirna - RNAi Therapies - Revolutionary Science, Revolutionary ...
AN INTRODUCTION TO RNA INTERFERENCE: RNAi is mediated by the assembly of a nuclease complex that leads to homologous mRNA degradation. When cells detect dsRNA, Dicer, an RNase III ...
Sirna - RNAi Therapies - Revolutionary Science, Revolutionary ...
Sirna Therapeutics is realizing the potential of RNAi by creating potent and ... Sirna has the entrepreneurial spirit of a start-up while also having the global ...
siRNA
Reduced time and cost savings. Less screening is needed to obtain highly effective siRNA. More for less concentration. Lower concentrations are needed for effective gene silencing
siRNA binding proteins of microglial cells: PKR is...[J Cell Biochem ...
PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to ...
Nucleic Acid Function and Technology Group
Welcome to the Nucleic Acid Function and Technology Group headed by Professor Jørgen Kjems. We are located at the Department of Molecular Biology,Faculty of Science, University of ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Sirna

SiRNAvitro.gif

Small interfering RNA (SIRNA), sometimes known as short interfering RNA or silencing RNA, is a class of 20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Sirna
FDA Clears Tekmira to Begin Phase I Study of siRNA-Based Cholesterol Drug
GenomeWeb News
The US Food and Drug Administration has approved Tekmira Pharamceuticals' investigational new drug application for its siRNA-based hypercholesterolemia drug ApoB SNALP, the company said today.
Roche Partners With Tekmira Pharmaceuticals to Advance RNAi Product Candidates
T-Net British Columbia
Vancouver, BC, May 11, 2009--(T-Net)--Tekmira Pharmaceuticals Corporation (TSX:TKM) announced today that it has entered into a product development agreement with global healthcare company Roche (SWX:ROG.VX; SWX:RO.S) to advance Roche's firs...
Knowledge based identification of essential signaling from genome ...
BioMed Central
We use PIPA to analyze genome-scale siRNA cell growth screens performed in HeLa and TOV cell lines. First we show that interacting gene pair siRNA hits are more reproducible than single gene hits. Using protein interactions, PIPA identifies...
Tekmira Pharmaceuticals Receives Clearance From FDA To Initiate ApoB SNALP Phase 1 Clinical Trial
BioresearchOnline
Tekmira Pharmaceuticals Corporation announced recently that its Investigational New Drug (IND) application for ApoB SNALP has been cleared by the United States Food and Drug Administration (FDA) allowing Tekmira to begin enrolling patients ...
Targeted suppression of heme oxygenase-1 by small interference RNAs ...
BioMed Central
Four pairs of siRNA targeting rHO-1 mRNA were introduced into BRL cells and compared for their inhibitory effect on the expression of rHO-1 gene and production of rHO-1 protein. The siRNA exhibiting the most potent effect on HO-1 expression...
Tekmira Pharmaceuticals Corporation Announces Second Quarter 2009 ...
Phramalive.com
Tekmira also presented at an educational session that addressed the importance of mitigating immune stimulation in the development of small interfering RNA (siRNA) drugs, which was the basis for a recently published review article by Tekmir...
Dicerna Pharmaceuticals to Present at Upcoming Conferences
Business Wire via Yahoo! Finance
WATERTOWN, Mass.----Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, today announced presentations at two upcoming conferences: ...